2022
DOI: 10.1017/erm.2022.26
|View full text |Cite
|
Sign up to set email alerts
|

Unveil the pain of endometriosis: from the perspective of the nervous system

Abstract: Endometriosis is a chronic inflammatory disease with pelvic pain and uncharacteristic accompanying symptoms. Endometriosis-associated pain often persists despite treatment of the disease, thus it brings a deleterious impact on their personal lives as well as imposing a substantial economic burden on them. At present, mechanisms underlie endometriosis-associated pain including inflammatory reaction, injury, aberrant blood vessels and the morphological and functional anomaly of the peripheral and central nervous… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 154 publications
(180 reference statements)
0
1
0
Order By: Relevance
“…In this investigation, we identified enriched genes in GO terms and signaling pathways that might be utilized as diagnostic and/or therapeutic targets in endometriosis. Signaling pathways include extracellular matrix organization [101], nervous system development [102], signal transduction [103], hemostasis [104], muscle contraction [105], signaling by retinoic acid [106] and diseases of glycosylation [107] were responsible for advancement of endometriosis. Altered expression of L1CAM [108], HSD17B2 [109], VCAM1 [110], SOX6 [111], FGF10 [112], MMP12 [113], CCR1 [114], PROK1 [115], PRL (prolactin) [116], TIMP3 [117], ADAMTS9 [118], NDNF (neuron derived neurotrophic factor) [119], LHCGR (luteinizing hormone/choriogonadotropin receptor) [120], PDGFB (platelet derived growth factor subunit B) [121], LDLR (low density lipoprotein receptor) [122], CD4 [123], FOXL2 [124], TRPA1 [125], ADRB2 [126], PLAU (plasminogen activator, urokinase) [127], EPCAM (epithelial cell adhesion molecule) [128], UCN2 [129], CYP1A1 [130], NTN1 [131], IL15 [132], BMP2 [133], APOE (apolipoprotein E) [134], CASP1 [135], ABCG2 [136], ACE (angiotensin I converting enzyme) [137], PGR (progesterone receptor) [138], ALPP (alkaline phosphatase, placental) [139], LPAR4 [140], ATRNL1 [141], HLA-C [142], MMP3 [143], PDLIM3 [144], NFASC (neurofascin) [145], IL33 [146], NGF (nerve growth factor) [147], COMP (cartilage oligomeric matrix protein) [148], FST (follistatin) [149], EFEMP1 [150], GATA6 [151], TCF21 [152], PTGS2 [153], HOXC8 [154], AKR1C3 [155], BDNF (brain derived neurotrophic factor) [119], EPHA3 [156], INHBA (inhibin subunit beta A) [157], RAP1GAP [158], TLR3 [159], NOX4 [160], TGFBI (transforming growth factor beta induced) [161], IGF2B...…”
Section: Discussionmentioning
confidence: 99%
“…In this investigation, we identified enriched genes in GO terms and signaling pathways that might be utilized as diagnostic and/or therapeutic targets in endometriosis. Signaling pathways include extracellular matrix organization [101], nervous system development [102], signal transduction [103], hemostasis [104], muscle contraction [105], signaling by retinoic acid [106] and diseases of glycosylation [107] were responsible for advancement of endometriosis. Altered expression of L1CAM [108], HSD17B2 [109], VCAM1 [110], SOX6 [111], FGF10 [112], MMP12 [113], CCR1 [114], PROK1 [115], PRL (prolactin) [116], TIMP3 [117], ADAMTS9 [118], NDNF (neuron derived neurotrophic factor) [119], LHCGR (luteinizing hormone/choriogonadotropin receptor) [120], PDGFB (platelet derived growth factor subunit B) [121], LDLR (low density lipoprotein receptor) [122], CD4 [123], FOXL2 [124], TRPA1 [125], ADRB2 [126], PLAU (plasminogen activator, urokinase) [127], EPCAM (epithelial cell adhesion molecule) [128], UCN2 [129], CYP1A1 [130], NTN1 [131], IL15 [132], BMP2 [133], APOE (apolipoprotein E) [134], CASP1 [135], ABCG2 [136], ACE (angiotensin I converting enzyme) [137], PGR (progesterone receptor) [138], ALPP (alkaline phosphatase, placental) [139], LPAR4 [140], ATRNL1 [141], HLA-C [142], MMP3 [143], PDLIM3 [144], NFASC (neurofascin) [145], IL33 [146], NGF (nerve growth factor) [147], COMP (cartilage oligomeric matrix protein) [148], FST (follistatin) [149], EFEMP1 [150], GATA6 [151], TCF21 [152], PTGS2 [153], HOXC8 [154], AKR1C3 [155], BDNF (brain derived neurotrophic factor) [119], EPHA3 [156], INHBA (inhibin subunit beta A) [157], RAP1GAP [158], TLR3 [159], NOX4 [160], TGFBI (transforming growth factor beta induced) [161], IGF2B...…”
Section: Discussionmentioning
confidence: 99%